Affinivax: GSK to spend up to $3.3 bln on Affinivax to boost vaccines roster

GSK on Tuesday agreed to buy U.S. biotech Affinivax for up to $3.3 billion, its second major deal in two months, giving the British pharmaceutical giant access to the company's roster of next-generation vaccines.